An N-, C-terminally truncated basic fibroblast growth factor and LPD (liposome-polycation-DNA) complexes elicits a protective immune response against murine colon carcinoma

Cancer Biology and Therapy

Volumn 10, Issue 3, 2010, Pages 276-281

  Zhang, Xiao Ping ^a   Yang, Li ^a   Shi, Hua Shan ^a   Zhao, Xia ^b   Deng, Hong Xin ^a   Xiao, Wen Jing ^a   Mao, Yong Qiu ^a   Kan, Bing ^a   Liu, Ya Lin ^a   Zhang, Shuang ^a   Li, Zhi Mian ^a   Zhang, Jing ^a   Wei, Yu Quan ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Basic fibroblast growth factor; Immunotherapy; Liposome polycation DNA; Murine colon carcinoma

Indexed keywords

ADJUVANT; BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; LIPOSOME; PLASMID DNA; POLYCATION;

ADOPTIVE TRANSFER; AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER TISSUE; CARBOXY TERMINAL SEQUENCE; COLON CARCINOMA; COMPLEX FORMATION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; IN VITRO STUDY; INNATE IMMUNITY; MOUSE; NONHUMAN; SPLEEN CELL; TUMOR IMMUNITY;

EID: 77955506125     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.3.12421     Document Type: Article

References (41)

1. Delrieu I. The high molecular weight isoforms of basic fibroblast growth factor (FGF-2): An insight into an intracrine mechanism. FEBS Lett 2000; 468:6-10. (Pubitemid 30101671)
2. Tomanek RJ, Schatteman GC. Angiogenesis: New insights and therapeutic potential. Anat Rec 2000; 261:126-35.
3. Dell'era P, Nicoli S, Peri G, Nieddu M, Ennas MG, Presta M. FGF2-induced upregulation of DNA polymerase-delta p12 subunit in endothelial cells. Oncogene 2005; 24:1117-21.
4. Gaudric A, N'Guyen T, Moenner M, Glacet-Bernard A, Barritault D. quantification of angiogenesis due to basic fibroblast growth factor in a modified rabbit corneal model. Ophthalmic Res 1992; 24:181-8.
5. Gospodarowicz D, Moran J, Braun D, Birdwell C. Clonal growth of bovine vascular endothelial cells: fibroblast growth factor as a survival agent. Proc Natl Acad Sci USA 1976; 73:4120-4.
6. Dow JK, Vere White RW. Fibroblast growth factor 2: Its structure and property, paracrine function, tumor angiogenesis and prostate-related mitogenic and oncogenic functions. Urology 2000; 55:800-6.
7. Nugent MA, Iozzo RV. Fibroblast growth factor-2. Int J Biochem Cell Biol 2000; 32:115-20.
8. Ornitz DM. FGFs, heparan sulfate and FGFRs: Complex interactions essential for development. Bioessays 2000; 22:108-12.
9. Montesano R, vassalli JD, Baird A, Guillemin R, Orci L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA 1986; 83:7297-301.
10. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235:442-7.
11. Ishihara M, Shaklee PN, yang Z, Liang W, Wei Z, Stack RJ, Holme K. Structural features in heparin which modulate specific biological activities mediated by basic fibroblast growth factor. Glycobiology 1994; 4:451-8.
12. Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res 1992; 59:115-25.
13. Gan Y, Wientjes MG, Au JL. Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res 2006; 23:1324-31.
14. Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 1998; 160:870-6.
15. Jorgensen JB, Johansen LH, Steiro K, Johansen A. CpG DNA induces protective antiviral immune responses in Atlantic salmon (Salmo salar L). J Virol 2003; 77:11471-9.
16. Klinman DM, Barnhart KM, Conover J. CpG motifs as immune adjuvants. Vaccine 1999; 17:19-25.
17. Krieg AM, yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374:546-9.
18. Krieg AM. CpG motifs: the active ingredient in bacterial extracts? Nat Med 2003; 9:831-5.
19. Pilon-Thomas S, Li W, Briggs JJ, Djeu J, Mule JJ, Riker AI. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model. J Immunother 2006; 29:381-7. (Pubitemid 44288950)
20. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2:675-80.
21. Dileo J, Banerjee R, Whitmore M, et al. Lipidprotamine-DNA-mediated antigen delivery to antigenpresenting cells results in enhanced anti-tumor immune responses. Mol Ther 2003; 7:640-8.
22. Lee RJ, Huang L. Folate-targeted, anionic liposomeentrapped polylysine-condensed DNA for tumor cellspecific gene transfer. J Biol Chem 1996; 271:8481-7. (Pubitemid 26108687)
23. Li S, Rizzo MA, Bhattacharya S, Huang L. Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery. Gene Ther 1998; 5:930-7.
24. Whitmore MM, Li S, Falo L Jr, Huang L. Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses. Cancer Immunol Immunother 2001; 50:503-14.
25. Whitmore M, Li S, Huang L. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther 1999; 6:1867-75. (Pubitemid 29531282)
26. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82:4-6.
27. Risau W. Mechanism of angiogenesis. Nature 1997; 386:671-4.
28. Fan TP, Jaggar R, Bicknell R. Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol Sci 1995; 16:57-66.
29. Li S, Shipley GD. Expression of multiple species of basic fibroblast growth factor mRNA and protein in normal and tumor-derived mammary epithelial cells in culture. Cell Growth Differ 1991; 2:195-202.
30. Gomm JJ, Smith J, Ryall GK, Baillie R, Turnbull L, Coombes RC. Localization of basic fibroblast growth factor and transforming growth factor beta1 in the human mammary gland. Cancer Res 1991; 51:4685-92.
31. Anandappa SY, Winstanley JHR, Leinster S, Green B, Rudland PS, Barraclough R. Comparative expression of fibroblast growth factor mRNAs in benign and malignant breast disease. Br J Cancer 1994; 69:772-6.
32. Ke Y, Fernig DG, Wilkinson MC, Winstanley JHR, Smith JA, Rudland PS, Barraclough R. The expression of basic fibroblast growth factor and its receptor in cell lines derived from normal human mammary gland and a benign mammary lesion. J Cell Sci 1993; 106:135-43.
33. Liscia DS, Merlo GR, Garrett C, French D, Mariani-Costantini R, Callahan R. Expression of int-2 mRNA in human tumors amplified at the int-2 locus. Oncogene 1989; 4:1219-24.
34. Burgess WH, Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 1989; 58:575-606. (Pubitemid 19172981)
35. Rifkin DB, Moscatelli D. Recent developments in the cell biology of basic fibroblast growth factor. J Cell Biol 1989; 109:1-6.
36. Stacy M. Plum, John W. Holaday, Antonio Ruiz, et al. Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development. Vaccine 2000; 19:1294-303.
37. Hori A, Sasada R, Matsutani E, et al. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 1991; 51:6180-4.
38. Murai N, Ueba T, Takahashi JA, yang HQ, Kikuchi H, Hiai H, et al. Apoptosis of human glioma cells in vitro and in vivo induced by a neutralizing antibody against human basic fibroblast growth factor. J Neurosurg 1996; 85:1072-7.
39. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nature Biotech 1997; 15:647-52.
40. Fairman J, Moore J, Lemieux M, et al. Enhanced in vivo immunogenicity of SIv vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study. Hum Vaccin 2009; 5:141-50.
41. Zaks K, Jordan M, Guth A, et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR or TLR agonists complexed to cationic liposomes. J Immunol 2006; 176:7335-45.